Form 4: Bioventus Director Pat Beyer Executes RSU Conversion

Director Pat Beyer acquired 32,282 shares of Bioventus Class A common stock through the vesting of restricted stock units.

Summary

• Director Pat Beyer exercised 32,282 restricted stock units (RSUs) on June 2, 2026, converting them into an equal number of Class A common stock shares.
• Following the transaction, the director holds a total of 108,718 shares of Class A common stock.
• On June 3, 2026, the director was granted an additional 25,146 RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event related to director compensation and equity ownership.

Positives

• Director maintains a significant equity stake of 108,718 shares, aligning interests with shareholders.

Negatives

• None identified; this is a standard equity compensation event.

Risks

• Future vesting of the newly granted 25,146 RSUs is contingent upon the director's continued service on the Board.

Future Outlook

The newly granted 25,146 RSUs are scheduled to vest on the earlier of the day before the next Annual Meeting of Stockholders or the first anniversary of the grant date, contingent on continued board service.

Industry Context

StockSavvy.ai notes that this transaction reflects standard corporate governance practices regarding director compensation and equity retention within the medical device sector.

Comparison to Industry Standards

• The use of RSU grants as a component of director compensation is consistent with standard practices for mid-cap medical technology companies.
• The vesting schedule aligns with typical annual equity refresh cycles observed in the industry.

Stakeholder Impact

• Minimal impact on shareholders as this represents standard equity-based compensation for board members.

Next Steps

• Vesting of the 25,146 RSUs granted on June 3, 2026, subject to continued board service.

Key Dates

Keywords

Bioventus, BVS, Insider Trading, Form 4, Equity Compensation, Director Ownership